

Supplementary-Table 1 The top ten most cited publications

Ref.	Title	Total Citations	TC per year	Normalized TC
YAO JC, 2011, N ENGL J MED	Everolimus for advanced pancreatic neuroendocrine tumors	2051	157.7692	40.73958
PAEZ-RIBES M, 2009, CANCER CELL	Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis	1900	126.6667	31.18945
Raymond E, 2011, N ENGL J MED	Sunitinib malate for the treatment of pancreatic neuroendocrine tumors	1777	136.6923	35.29705
Jiao Y, 2011, SCIENCE	DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors	1201	92.38462	23.8558
FALCONI M, 2016, NEUROENDOCRINOLOGY	ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors	768	96	49.20824
HALFDANARSON TR, 2008, ANN ONCOL	Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival	573	35.8125	9.109345
YAO JC, 2010, J CLIN ONCOL	Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial	491	35.07143	17.50193
KULKE MH, 2008, J CLIN ONCOL	Activity of sunitinib in patients with advanced neuroendocrine tumors	474	29.625	7.535479

YAP TA, 2011, J CLIN ONCOL	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors	432	33.23077	8.580936
ALLEN E, 2017, SCI TRANSL MED	Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation	415	59.28571	29.38922

TC: Total citations; DAXX: death-domain-associated protein; ATRX: α thalassemia/mental retardation syndrome X-linked; MEN1: multiple endocrine neoplasia 1; mTOR: mammalian target of rapamycin; ENETS: European Neuroendocrine Tumor Society; PD-L1: programmed cell death ligand 1; HEV: high endothelial venule.